Medications such as glucagon-like peptide 1 (GLP-1) agonists, glucose-dependent insulinotropic polypeptide (GIP) agonists, and dual GLP-1/GIP agonists could benefit patients with diabetes, obesity, and cardiovascular disease (54). This evidence concerns the gene GCG and obesity disorder.